Novartis kicks it into high gear to revive flailing Alcon unit

Emily Wasserman Novartis' Alcon business has been struggling for some time now, and the company's efforts to help its eye-care business get back on track don't seem to be ...

Novartis backs $176M microbiome biotech fund

John Carroll Novartis has stepped in to back Paris-based Seventure Partners' biotech fund focused exclusively on the emerging field of the microbiome as well as nutrition, bringing ...

Novartis keeps its CAR-T lead with positive Phase II data

Damian Garde Novartis, leading a pack of companies developing genetically engineered T cells to fight cancer, unveiled more promising data on its Phase II treatment as it wends toward ...

UPDATED: Novartis falls short in controversial IPR process as board nixes Gilenya patent

Tracy Staton The U.S. Patent and Trademark Office's review board has dealt its first blow to Big Pharma. The appeal panel nixed a patent on Novartis' multiple sclerosis blockbuster ...

Novartis CEO stands by emerging markets even as China economy continues to weaken

Eric Palmer China's economy is a mess and other emerging markets are flailing about as well. So what is pharma CEO to do if they have bet big on growth in the EM realm? Keep on ...

Why is Novartis’ Copaxone copy lagging? It’s all about coverage, analyst explains

Carly Helfand Typically, the first generics for blockbuster meds get off to a running start. Not so with Novartis' generic of Teva's multiple sclerosis standout Copaxone, though–and ...

Novartis CEO: Payers not sold on performance pricing yet, but that’ll change

Tracy Staton Novartis CEO Joe Jimenez sees a couple of rays of hope for drug spending–and for the viability of higher-priced meds. Big Data, for one. And performance-based pricing ...

Novartis’ newly acquired melanoma combo wins EU recommendation

Carly Helfand Novartis' recently acquired melanoma duo, Tafinlar and Mekinist, has won a recommendation from the European Medicines Agency's Committee for Medicinal Products ...

Novartis wins an early approval for a new skin cancer drug

Damian Garde Novartis won accelerated approval for a promising oncology drug, gearing up to launch a new treatment for an advanced form of the most common type of skin cancer. FierceBiotech ...

Amgen’s Neupogen won’t face Novartis biosim till September: court

Carly Helfand Novartis' Sandoz may have the first FDA-approved biosimilar in Zarxio, but it doesn't have permission to launch–and it won't be getting ...

Novartis’ pay-for-performance Entresto plan has its critics–Express Scripts’ Miller among them

Carly Helfand Novartis has said it's planning to offer an outcomes-based plan for its new blockbuster-in-the-making to secure payers' favor. But skeptics see some kinks in the ...

FierceBiotech Radio on big approvals for Novartis and Vertex, Mylan’s real estate controversy, and @brentlsaunders

Alok Saboo FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss the week's biggest news in biopharma, including Novartis and Vertex Pharmaceuticals scoring ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS